TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers linked lower levels of the protective protein NRF2 in oligodendrocytes to abnormal myelin and loss of large nerve fibers in people with faster cognitive decline. Experiments in mice support a possible role for NRF2 in these changes, but the findings do not show that a drug targeting the pathway can prevent age-related decline in people.
Researchers from the University of Edinburgh and the UK Dementia Research Institute report that dysfunction in oligodendrocytes—brain cells that produce and maintain the insulating coating around nerve fibers—may contribute to cognitive decline with age. The study, published in Nature Medicine, links lower levels of the protective protein NRF2 in these cells to abnormal myelin and nerve-fiber loss in human brain tissue, with mouse experiments providing evidence of a possible causal role.
The human findings draw on the Lothian Birth Cohort 1936, whose members have been followed with cognitive assessments from childhood into old age. Between ages 70 and 82, researchers measured memory, processing speed and spatial reasoning. Of 1,091 people enrolled, 866 completed additional testing after age 70. Most experienced some decline, but its pace varied.
After participants died, researchers examined brain tissue from a subset of the cohort. People whose cognitive abilities had declined more quickly tended to have fewer large nerve fibers and an abnormal buildup of myelin, the fatty coating that helps electrical signals travel along nerve fibers. The tissue findings were associated with the rate of decline over time, not simply with cognitive test performance at one age.
The team found lower levels of NRF2 in oligodendrocytes among people with more severe decline. NRF2 regulates genes involved in cellular protection and normal function. In mice, selectively reducing NRF2 in oligodendrocytes led to excess myelin, loss of large nerve fibers and less improvement in cognitive performance as the animals aged. The animal results support a possible mechanism, but do not establish that the same process explains cognitive decline in people.
A New Target in Aging Brain Research
The findings challenge the assumption that myelin-producing cells remain uniformly protective throughout life. If oligodendrocytes become impaired as they age, changes in these cells could be part of the process that damages nerve fibers and affects thinking—not just a response to other brain changes. That offers researchers a possible avenue for studying how cognitive abilities are preserved.
The NRF2 pathway is already targeted by medicines used for other neurological conditions, including a drug prescribed for multiple sclerosis. The researchers say that creates a potential starting point for future investigation. It is not evidence that existing medicines prevent age-related cognitive decline, and people should not change or seek treatment based on this study alone. Clinical research would be needed to establish safety and benefit in older adults.
Products Worth Considering
eufy Security eufyCam C37 4-Camera Kit with 360° Pan and Tilt
eufy Security Essential Alarm System, 7-Piece, No Monthly Fee
Google Nest Learning Thermostat (4th Gen) with Nest Temperature Sensor (2nd Gen), Obsidian
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The study combines two kinds of evidence. Long-term records from the Lothian cohort let researchers compare brain tissue findings with the pace of cognitive change across years. Post-mortem tissue offered a view of myelin and nerve fibers, while experiments in mice let the team test what happened when NRF2 was reduced specifically in oligodendrocytes.
These approaches answer different questions. The human data show an association between cell-protection markers, tissue changes and faster decline; they cannot by themselves prove which change came first. The mouse experiments add evidence that altering NRF2 can produce similar tissue abnormalities, but findings in animals do not establish a treatment effect in humans.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Human Treatment Effects Remain Unknown
The study does not show that reduced NRF2 is the sole cause of cognitive decline, or that raising NRF2 would reverse the changes in people. The human tissue analysis came from a subset of cohort members after death, and the supplied report does not specify the size of that subset. It also does not report a clinical trial testing an NRF2-targeting drug for age-related cognitive decline.
It remains unclear which older adults, if any, might benefit from altering this pathway, what treatment and dose would be appropriate, and whether effects seen in mice would translate to people. The study also does not establish that abnormal myelin changes explain every form or cause of cognitive decline.
Testing the NRF2 Pathway in People
The next step is further research to determine how NRF2 activity changes in aging oligodendrocytes and whether those changes can be safely modified. Before existing drugs could be considered for age-related cognitive decline, researchers would need evidence from studies designed for that population, including trials that measure both safety and cognitive outcomes.
For now, the reported work identifies a possible biological target rather than a new treatment. The key question is whether targeting NRF2 can protect nerve fibers and preserve thinking abilities in older adults, not just reproduce promising effects in laboratory models.
Key Questions
Which brain cells are linked to the decline?
The study focused on oligodendrocytes, cells that produce and maintain myelin, the insulating coating around nerve fibers.
What is NRF2?
NRF2 is a protein that regulates genes involved in cellular defenses and normal function. Researchers found lower levels of it in oligodendrocytes in people with more severe cognitive decline.
Does the study prove that these cells cause cognitive decline in people?
No. The human findings show associations. Experiments in mice provide evidence that reducing NRF2 in oligodendrocytes can produce related changes, but they do not prove the same causal process in people.
The study points to an NRF2-targeting pathway that includes a drug used for multiple sclerosis, but it did not test that drug as a treatment for age-related cognitive decline. Its safety and effectiveness for that purpose remain unknown.
Source: rss
